

The Anticancer and Therapeutic Potential of Plant-Derived Nutraceuticals from Mediterranean Diet †

Maria Vranceanu ^{1,*}, Carmina Stroia ²

¹ Department of Toxicology, “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj Napoca, Romania

² Department of Pharmacy, Oradea University, Romania

* Correspondence: marievranceanu@gmail.com (M.V.);

† Presented at 2nd Edition of the OncoHub Conference – Connecting Scientists and Physicians for Next Generation Cancer Management, Poiana Braşov, Braşov, 21-23 September 2022

Received: 10.12.2022; Accepted: 20.12.2022; Published: 5.01.2023

Abstract: The association between diet and the development and progression of different malignancies has already been demonstrated. According to numerous current studies, about 35% of all cancer-related deaths are linked to diet, and several cancer forms are preventable with balanced nutrition and dietary compounds being able to reverse epigenetic abnormalities. The Mediterranean diet shows inverse associations with metabolic diseases, cardiovascular pathologies, and various types of cancer. Many bioactive nutrients of the Mediterranean diet have been identified as protective factors against these pathologies. The epigenome has been identified as the primary goal of modulations in gene expression related to these molecular nutrients. In fact, they can modify the epigenome and be incorporated into the ‘epigenetic diet’, which translates into a diet regimen that can be used therapeutically for health or preventative purposes. It has been demonstrated that nutraceuticals such as curcumin, resveratrol, sulforaphane, indole-3- carbinol, quercetin, astaxanthin, epigallocatechin-3-gallate, and lycopene have enhanced effect on epigenetic changes and positively modulate the epigenome, reducing cancer incidence. Understanding the mechanisms by which nutraceuticals influence gene expression will allow their incorporation into an “epigenetic diet” that could be further capitalized in cancer therapy.

Keywords: nutraceuticals; gene expression; epigenetic therapy; cancer.

© 2023 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Funding

This research received no external funding.

Acknowledgments

This research has no acknowledgment.

Conflicts of Interest

The authors declare no conflict of interest.